ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1024

Modeling The Benefit Risk Profiles Of a New Janus Kinase Inhibitor Tofacitinib Compared Tottumour Necrosis Factor Inhibitor Biologic Treatments Incorporating Conjoint Derived Patient Preference Weights

Michael P. Ingham1, Shannon Cartier2, Raphael J. DeHoratius3, Jack McGowan4 and Eric Sabot2, 1Janssen Scientific Affairs, LLC, Horsham, PA, 2Optum, Eden Prairie, MN, 3Medical Affairs, Janssen Services, LLC, Horsham, PA, 4Janssen Services, LLC, Horsham, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologics, Janus kinase (JAK) and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tofacitinib (Tofa) was recently approved in the U.S. There are no data comparing the benefit risk profile of Tofa to tumor necrosis factor inhibitors (TNFi). This analysis included a conjoint survey of rheumatology patients’ preferences, followed by a benefit-risk assessment combining multiple benefits and risks associated with Tofa vs. TNFi.

Methods: The patient preference study investigated 10 attributes, Patient cost, ACR20, Oral vs Injection vs Infusion, Injection site/infusion reactions, Nausea, Herpes Zoster, Malignancies, and Cholesterol elevation.  Attribute “levels” were assigned from pivotal trial data, meta-analyses, FDA documents and prescribing information.  Levels encompassed a plausible range of values. Each patient was asked to complete a preference selection for 15 choice tasks, based on a randomized design using a 5-attribute partial profile. A Multi-Criteria Decision Analysis (MCDA), a tool from the EMEA risk-benefit project, was used to assess the overall benefit-risk profile, incorporating differences in outcomes and using the conjoint survey to weight each attribute’s relative importance. The base case profile identified Tofa as having a less robust ACR20 response, higher incidence of malignancy and herpes zoster risk, greater impact on cholesterol, lower levels of injection site/infusion reactions and oral vs injection/infusion. 

Results: 386 patients had evaluable data from the conjoint preference study. 71% were female and median age was between 60 and 64.  Fifty-one patients (13%) were bio-naïve.  Attributes that showed the greatest impact on preference perception between top and bottom levels included out-of-pocket costs, injection site reactions, dose interval/mode and impact on cholesterol.  There was little difference between injection site reactions levels of none and 4/100 patient years (PY), as well as between dose interval/mode of oral at 730 doses per year and injections at 12 times per year.  For dose interval/mode, the least preferred option was injections 26-52 times per year.  Based on base case profiles assigned to individual products, 42% of patients would choose golimumab, 34% an oral DMARD and 24% infliximab.  If all Tofa risk attribute differences vs TNFi were removed, 53% would choose Tofa, 28% golimumab and 19% infliximab.  Etanercept and Adalimumab preferences were sensitive to rate of injection site reactions. The MCDA estimated a greater combined score for TNFi compared to Tofa, indicating that from a patient perspective TNFi are a more favorable treatment option overall. A major contributing factor to this outcome was the relative importance that patients placed on risk attributes which favored the TNFi profile.

Conclusion: Patients appear sensitive to relatively small changes in tolerability and safety profiles of rheumatology treatments.  Benefit and risk profiles can have significant mitigating influence over patient preferences related to convenience of treatment.  This reinforces the need for full and clear disclosure to patients of the benefit and risks of treatments in RA and the importance of patient involvement in treatment decisions, since lack of preference can have an impact on adherence.


Disclosure:

M. P. Ingham,

Janssen Scientific Affairs, LLC,

3;

S. Cartier,

Janssen Scientific Affairs, LLC,

5;

R. J. DeHoratius,

Janssen Biotech.,

3;

J. McGowan,

Janssen Scientific Affairs, LLC,

3;

E. Sabot,

Janssen Scientfic Affairs, LLC,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modeling-the-benefit-risk-profiles-of-a-new-janus-kinase-inhibitor-tofacitinib-compared-tottumour-necrosis-factor-inhibitor-biologic-treatments-incorporating-conjoint-derived-patient-preference-weight/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology